{"component": "clause", "props": {"groups": [{"size": 4, "snippet_links": [{"key": "prior-to-the-effective-date", "type": "clause", "offset": [0, 27]}, {"key": "engaged-in", "type": "definition", "offset": [62, 72]}, {"key": "development-programs", "type": "definition", "offset": [81, 101]}, {"key": "gene-therapy-products", "type": "definition", "offset": [105, 126]}, {"key": "cns-field", "type": "definition", "offset": [134, 143]}, {"key": "this-agreement", "type": "clause", "offset": [151, 165]}, {"key": "development-of-products", "type": "clause", "offset": [220, 243]}, {"key": "to-develop", "type": "definition", "offset": [309, 319]}, {"key": "the-products", "type": "clause", "offset": [357, 369]}, {"key": "section-31", "type": "clause", "offset": [442, 453]}, {"key": "option-grants", "type": "clause", "offset": [455, 468]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [471, 495]}, {"key": "pd-collaboration-program", "type": "definition", "offset": [546, 570]}, {"key": "hd-collaboration-program", "type": "definition", "offset": [580, 604]}, {"key": "fa-collaboration-program", "type": "definition", "offset": [614, 638]}, {"key": "sma-collaboration-program", "type": "definition", "offset": [652, 677]}, {"key": "in-addition", "type": "clause", "offset": [679, 690]}, {"key": "the-right", "type": "clause", "offset": [711, 720]}, {"key": "in-accordance-with", "type": "definition", "offset": [734, 752]}, {"key": "designation-of", "type": "definition", "offset": [768, 782]}, {"key": "future-collaboration", "type": "clause", "offset": [783, 803]}, {"key": "voyager-cns-orphan-disease-program", "type": "definition", "offset": [835, 869]}, {"key": "the-future", "type": "clause", "offset": [919, 929]}, {"key": "program-option", "type": "clause", "offset": [1004, 1018]}, {"key": "applies-to", "type": "clause", "offset": [1063, 1073]}, {"key": "the-co", "type": "clause", "offset": [1273, 1279]}, {"key": "hd-licensed-product", "type": "definition", "offset": [1365, 1384]}], "samples": [{"hash": "fyyY1aCKvdq", "uri": "/contracts/fyyY1aCKvdq#collaboration-programs", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.8453114305, "published": true}, {"hash": "d4YNOZGiWoQ", "uri": "/contracts/d4YNOZGiWoQ#collaboration-programs", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.839835729, "published": true}, {"hash": "6A88nyJpxXr", "uri": "/contracts/6A88nyJpxXr#collaboration-programs", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.7686516085, "published": true}], "snippet": "Prior to the Effective Date, each of Voyager and Genzyme have engaged in certain development programs of Gene Therapy Products in the CNS field. Under this Agreement, Voyager and Genzyme shall collaborate in the further Development of products under such programs, and Genzyme shall have the exclusive option to develop and commercialize such programs (and the products generated by or that are the subjects of such programs) as set forth in Section 3.1 (Option Grants). As of the Effective Date, the four Collaboration Programs shall be (a) the PD Collaboration Program, (b) the HD Collaboration Program, (c) the FA Collaboration Program, and (d) the SMA Collaboration Program. In addition, Genzyme shall have the right, exercisable in accordance with Section 2.2.4 (Designation of Future Collaboration Program), to designate any one Voyager CNS Orphan Disease Program as a Collaboration Program under this Agreement (the Future Collaboration Program). In accordance with Section 3.1.1 (Split Territory Program Option Grants), the Split Territory Program Option applies to the HD Collaboration Program, the PD Collaboration Program, the FA Collaboration Program and the Future Collaboration Program, which collectively comprise the Split Territory Collaboration Programs. The Co-Co Option applies to the HD Collaboration Program, in accordance with Section 3.1.2 (HD Licensed Product Co-Co Option Grant). The SMA Program Option applies to the SMA Collaboration Program, in accordance with Section 3.1.3 (SMA Program Option Grant).", "hash": "eee91754a3a5d2e53454b9246b31b44e", "id": 1}, {"size": 3, "snippet_links": [{"key": "during-the-option-period", "type": "clause", "offset": [0, 24]}, {"key": "collaboration-program", "type": "definition", "offset": [31, 52]}, {"key": "responsible-for", "type": "clause", "offset": [100, 115]}, {"key": "activities-under", "type": "clause", "offset": [127, 143]}, {"key": "development-candidate-identification-plan", "type": "definition", "offset": [152, 193]}, {"key": "initial-development-plan", "type": "definition", "offset": [202, 226]}, {"key": "expenses-associated", "type": "definition", "offset": [245, 264]}, {"key": "in-addition", "type": "clause", "offset": [276, 287]}, {"key": "approved-costs", "type": "clause", "offset": [338, 352]}, {"key": "resulting-from", "type": "definition", "offset": [353, 367]}, {"key": "approved-changes", "type": "clause", "offset": [375, 391]}, {"key": "payment-mechanisms", "type": "clause", "offset": [402, 420]}], "samples": [{"hash": "5QQ8kSgUDvm", "uri": "/contracts/5QQ8kSgUDvm#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 30.1608487337, "published": true}, {"hash": "7yICmZPouEt", "uri": "/contracts/7yICmZPouEt#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 29.1587953457, "published": true}], "snippet": "During the Option Period, on a Collaboration Program-by-Collaboration Program basis, Biogen will be responsible for any Biogen Activities under the ASO Development Candidate Identification Plan and the Initial Development Plan and all costs and expenses associated therewith. In addition, Biogen will be responsible for paying any Biogen-Approved Costs resulting from Biogen-Approved Changes using the payment mechanisms set forth in Section 1.14.", "hash": "cf32770a2a94b2c3469f2dff8f2e503c", "id": 2}, {"size": 2, "snippet_links": [{"key": "the-collaboration", "type": "clause", "offset": [42, 59]}, {"key": "chosen-by", "type": "clause", "offset": [68, 77]}, {"key": "sole-discretion", "type": "clause", "offset": [93, 108]}, {"key": "without-limitation", "type": "clause", "offset": [247, 265]}, {"key": "clinical-trial-protocols", "type": "clause", "offset": [284, 308]}], "samples": [{"hash": "egRKMzZqJoo", "uri": "/contracts/egRKMzZqJoo#collaboration-programs", "label": "Intellectual Property Licensing Agreement (Generex Biotechnology Corp)", "score": 18.4182067077, "published": true}, {"hash": "7pbPNh3I8uM", "uri": "/contracts/7pbPNh3I8uM#collaboration-programs", "label": "Intellectual Property Licensing Agreement (Amarantus BioSciences, Inc.)", "score": 18.4182067077, "published": true}], "snippet": "The specific Indications to be pursued in the Collaboration will be chosen by Generex in its sole discretion, but with consultation with Amarantus. Non-clinical, clinical, quality, and regulatory Collaboration programs for Indications, including, without limitation, non-clinical and clinical trial protocols, will be designed jointly by Generex and Amarantus.", "hash": "fe77e41fa63de39f1b73d8218626fd33", "id": 3}, {"size": 2, "snippet_links": [{"key": "the-objective", "type": "clause", "offset": [0, 13]}, {"key": "collaboration-program", "type": "definition", "offset": [22, 43]}, {"key": "further-development", "type": "definition", "offset": [110, 129]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [140, 163]}, {"key": "completion-of-the", "type": "clause", "offset": [206, 223]}, {"key": "poc-study", "type": "definition", "offset": [224, 233]}, {"key": "clinical-candidate-selection-criteria", "type": "definition", "offset": [346, 383]}, {"key": "agreed-by", "type": "clause", "offset": [416, 425]}, {"key": "the-relevant", "type": "clause", "offset": [438, 450]}, {"key": "the-liabilities", "type": "clause", "offset": [486, 501]}, {"key": "associated-with", "type": "definition", "offset": [502, 517]}, {"key": "during-the-research-term", "type": "clause", "offset": [539, 563]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [584, 619]}, {"key": "research-and-development-activities", "type": "clause", "offset": [670, 705]}, {"key": "in-accordance-with", "type": "definition", "offset": [737, 755]}, {"key": "development-plan", "type": "definition", "offset": [771, 787]}, {"key": "approved-by", "type": "definition", "offset": [812, 823]}, {"key": "section-22", "type": "clause", "offset": [851, 862]}, {"key": "in-relation-to", "type": "clause", "offset": [867, 881]}, {"key": "this-section-2", "type": "clause", "offset": [1071, 1085]}, {"key": "unless-otherwise-agreed", "type": "definition", "offset": [1141, 1164]}], "samples": [{"hash": "esaxvJEvyRd", "uri": "/contracts/esaxvJEvyRd#collaboration-programs", "label": "Research and Development Collaboration and License Agreement (Orchard Rx LTD)", "score": 29.8076659822, "published": true}, {"hash": "fCYz8q3vb3x", "uri": "/contracts/fCYz8q3vb3x#collaboration-programs", "label": "Research and Development Collaboration and License Agreement (Orchard Rx LTD)", "score": 29.7556468172, "published": true}], "snippet": "The objective of each Collaboration Program is to (i) discover and Develop a Lead Vector for each Program for further Development under the terms of this Agreement and (ii) progress each Lead Vector to the completion of the POC Study. The JSC will commence a review at the point at which the first Lead Vector(s) is within [***] of achieving the Clinical Candidate Selection Criteria (or as otherwise may be earlier agreed by the JSC) in the relevant Collaboration Program to determine the liabilities associated with such Lead Vector(s). During the Research Term, TELETHON-HSR shall use Commercially Reasonable Efforts to conduct each Collaboration Program and related Research and Development activities for such Collaboration Program in accordance with the applicable Development Plan once such plan has been approved by the JSC in accordance with Section 2.2. If in relation to any Collaboration Program, TELETHON-HSR is unable to identify a Lead Vector which meets the Clinical Candidate Selection Criteria within the Research Term, TELETHON-HSR\u2019s obligations under this Section 2 shall cease in relation to that Collaboration Program, unless otherwise agreed by the JSC.", "hash": "ced558ccd49118da8bd3bb28d9e78fe0", "id": 4}, {"size": 2, "snippet_links": [{"key": "during-the-option-period", "type": "clause", "offset": [0, 24]}, {"key": "collaboration-program", "type": "definition", "offset": [31, 52]}, {"key": "responsible-for", "type": "clause", "offset": [99, 114]}, {"key": "activities-under", "type": "clause", "offset": [125, 141]}, {"key": "development-candidate-identification-plan", "type": "definition", "offset": [150, 191]}, {"key": "initial-development-plan", "type": "definition", "offset": [200, 224]}, {"key": "except-as-otherwise-provided", "type": "clause", "offset": [230, 258]}, {"key": "expenses-associated", "type": "definition", "offset": [295, 314]}], "samples": [{"hash": "5QQ8kSgUDvm", "uri": "/contracts/5QQ8kSgUDvm#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 30.1608487337, "published": true}, {"hash": "7yICmZPouEt", "uri": "/contracts/7yICmZPouEt#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 29.1587953457, "published": true}], "snippet": "During the Option Period, on a Collaboration Program-by-Collaboration Program basis, Ionis will be responsible for all Ionis Activities under the ASO Development Candidate Identification Plan and the Initial Development Plan and, except as otherwise provided under Section 1.13.1, all costs and expenses associated therewith.", "hash": "287a08fe72c6ab6619136a304da618f7", "id": 5}, {"size": 2, "snippet_links": [{"key": "subject-to", "type": "definition", "offset": [9, 19]}], "samples": [{"hash": "46Eato8gyQW", "uri": "/contracts/46Eato8gyQW#collaboration-programs", "label": "Preliminary Collaboration Agreement", "score": 32.0863386996, "published": true}], "snippet": "Programs subject to Opt-Out Right", "hash": "57274ec433ecf8941f47a55052f403be", "id": 6}, {"size": 2, "snippet_links": [{"key": "subject-to-and-in-accordance-with", "type": "clause", "offset": [0, 33]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [38, 61]}, {"key": "responsible-for", "type": "clause", "offset": [88, 103]}, {"key": "collaboration-target", "type": "clause", "offset": [260, 280]}, {"key": "pursuant-to", "type": "definition", "offset": [282, 293]}, {"key": "commercially-reasonable-efforts", "type": "definition", "offset": [327, 358]}, {"key": "discovery-activities", "type": "definition", "offset": [379, 399]}, {"key": "drug-screening", "type": "clause", "offset": [410, 424]}, {"key": "according-to", "type": "definition", "offset": [504, 516]}, {"key": "the-applicable", "type": "clause", "offset": [517, 531]}, {"key": "research-plans", "type": "definition", "offset": [554, 568]}, {"key": "target-sanction", "type": "definition", "offset": [580, 595]}, {"key": "development-candidate", "type": "definition", "offset": [619, 640]}, {"key": "development-activities", "type": "clause", "offset": [704, 726]}, {"key": "completion-of-the", "type": "clause", "offset": [766, 783]}, {"key": "poc-trial", "type": "definition", "offset": [790, 799]}, {"key": "development-plan", "type": "definition", "offset": [864, 880]}, {"key": "provided-that", "type": "clause", "offset": [882, 895]}, {"key": "work-on", "type": "definition", "offset": [935, 942]}, {"key": "license-effective-date", "type": "definition", "offset": [1042, 1064]}, {"key": "with-respect-to", "type": "clause", "offset": [1065, 1080]}, {"key": "to-develop", "type": "definition", "offset": [1161, 1171]}], "samples": [{"hash": "7CoFyFfYwto", "uri": "/contracts/7CoFyFfYwto#collaboration-programs", "label": "Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 32.8384668036, "published": true}], "snippet": "Subject to and in accordance with the terms of this Agreement, Ionis and Biogen will be responsible for conducting three programs to discover, Develop, Manufacture and Commercialize Products (each, a \u201cCollaboration Program\u201d), each to be focused on a different Collaboration Target, pursuant to which:\n1.2.1. Ionis will use its Commercially Reasonable Efforts to (a) conduct drug discovery activities including drug screening, identification, characterization, optimization and other necessary activities according to the applicable Collaboration Program Research Plans to achieve Target Sanction status, (b) identify a Development Candidate for the applicable Collaboration Program, and (c) conduct drug development activities for each Development Candidate through completion of the first PoC Trial under a Collaboration Program in accordance with the applicable Development Plan; provided that Ionis will not be required to commence work on more than [***] Collaboration Programs in any rolling [***] month period; and\n1.2.2. following the License Effective Date with respect to each Collaboration Program, Biogen will use its Commercially Reasonable Efforts to Develop, Manufacture and Commercialize at least one Product from each such Collaboration Program for which Biogen has exercised an Option in accordance with this Agreement.", "hash": "ff9d54ee1e6ffc5c8cc505c23126848d", "id": 7}, {"size": 2, "snippet_links": [{"key": "within-the-territory", "type": "clause", "offset": [49, 69]}, {"key": "with-respect-to", "type": "clause", "offset": [71, 86]}, {"key": "between-the-parties", "type": "clause", "offset": [156, 175]}, {"key": "subject-to", "type": "definition", "offset": [177, 187]}, {"key": "section-71", "type": "clause", "offset": [193, 204]}, {"key": "responsible-for", "type": "clause", "offset": [226, 241]}, {"key": "commercialization-of-collaboration-products", "type": "clause", "offset": [246, 289]}, {"key": "the-applicable", "type": "clause", "offset": [293, 307]}, {"key": "collaboration-territory", "type": "definition", "offset": [308, 331]}, {"key": "commercial-launch", "type": "clause", "offset": [389, 406]}, {"key": "required-approvals", "type": "clause", "offset": [422, 440]}, {"key": "regulatory-authorities", "type": "definition", "offset": [446, 468]}, {"key": "marketing-and-promotion", "type": "clause", "offset": [529, 552]}, {"key": "sales-and-distribution", "type": "clause", "offset": [562, 584]}, {"key": "related-services", "type": "definition", "offset": [604, 620]}, {"key": "customer-support", "type": "definition", "offset": [632, 648]}, {"key": "approval-of", "type": "clause", "offset": [747, 758]}, {"key": "in-the-field", "type": "clause", "offset": [783, 795]}, {"key": "commercially-reasonable-efforts-to-commercialize", "type": "clause", "offset": [882, 930]}, {"key": "provide-the", "type": "clause", "offset": [1038, 1049]}, {"key": "commercialization-activities", "type": "clause", "offset": [1089, 1117]}, {"key": "in-good-faith", "type": "definition", "offset": [1202, 1215]}, {"key": "all-sales", "type": "clause", "offset": [1297, 1306]}, {"key": "to-determine", "type": "definition", "offset": [1431, 1443]}, {"key": "certain-confidential-information-omitted", "type": "clause", "offset": [1517, 1557]}, {"key": "outside-the-territory", "type": "clause", "offset": [1607, 1628]}], "samples": [{"hash": "lNYrtxpSCEZ", "uri": "/contracts/lNYrtxpSCEZ#collaboration-programs", "label": "Collaboration and License Agreement (Zai Lab LTD)", "score": 32.6030116359, "published": true}], "snippet": "(a) [***] Program Before Opt-In and MGNX Program Within the Territory. With respect to (1) the [***] Program before the Opt-In and (2) the MGNX Program, as between the Parties, subject to this Section 7.1, Zai shall be solely responsible for the Commercialization of Collaboration Products in the applicable Collaboration Territory, at [***], including developing and executing a plan for commercial launch, obtaining all required approvals from Regulatory Authorities for Commercialization (including reimbursement activities), marketing and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related functions. Following Regulatory Approval of a Collaboration Product in the Field in any country or Region in the applicable Collaboration Territory, (i) Zai shall use Commercially Reasonable Efforts to Commercialize such Collaboration Product in the Field in such country or Region, and (ii) at each JCC meeting, Zai shall provide the JCC with an update with respect to its Commercialization activities for such Collaboration Product in the Field in such country or Region, and consider in good faith any comments thereto provided by the JCC. As between the Parties, Zai shall book all sales of Collaboration Products in any country or Region in the applicable Collaboration Territory, and shall have the sole right to determine all pricing of Collaboration Products in such country or Region. [***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED\n(b) [***] Program Before Opt-In and MGNX Program Outside the Territory. With respect to (1) the [***] Program before the Opt-In and (2) the MGNX Program, as between the Parties, subject to this Section 7.1, MacroGenics shall be solely responsible for the Commercialization of Collaboration Products in the Field outside the applicable Collaboration Territory.", "hash": "d413fbb038476934b0a148c2ef4927a3", "id": 8}, {"size": 2, "snippet_links": [{"key": "at-any-time", "type": "clause", "offset": [63, 74]}, {"key": "during-the-option-period", "type": "clause", "offset": [75, 99]}, {"key": "a-change-of-control-occurs", "type": "clause", "offset": [101, 127]}, {"key": "a-person", "type": "clause", "offset": [148, 156]}, {"key": "time-of-the", "type": "clause", "offset": [170, 181]}, {"key": "human-clinical-trials", "type": "definition", "offset": [232, 253]}, {"key": "collaboration-product", "type": "definition", "offset": [296, 317]}, {"key": "the-field", "type": "definition", "offset": [325, 334]}, {"key": "engaged-in", "type": "definition", "offset": [341, 351]}, {"key": "directly-competitive-collaboration-program", "type": "definition", "offset": [354, 396]}, {"key": "competitive-product", "type": "definition", "offset": [476, 495]}, {"key": "during-the-term", "type": "clause", "offset": [514, 529]}, {"key": "after-the-closing", "type": "clause", "offset": [530, 547]}, {"key": "competing-collaboration-acquirer", "type": "definition", "offset": [745, 777]}, {"key": "in-the-event-the", "type": "clause", "offset": [895, 911]}, {"key": "closing-date", "type": "definition", "offset": [1087, 1099]}, {"key": "date-of", "type": "clause", "offset": [1112, 1119]}, {"key": "collaboration-divestiture-period", "type": "definition", "offset": [1324, 1356]}, {"key": "development-and-commercialization", "type": "clause", "offset": [1486, 1519]}, {"key": "will-provide", "type": "clause", "offset": [1638, 1650]}, {"key": "notice-to", "type": "definition", "offset": [1659, 1668]}, {"key": "with-respect-to", "type": "clause", "offset": [1791, 1806]}, {"key": "relates-to", "type": "definition", "offset": [1838, 1848]}, {"key": "toxicology-studies", "type": "definition", "offset": [1980, 1998]}, {"key": "subject-to-section", "type": "clause", "offset": [2018, 2036]}, {"key": "agreement-for", "type": "clause", "offset": [2102, 2115]}, {"key": "the-applicable", "type": "clause", "offset": [2162, 2176]}, {"key": "ready-to", "type": "clause", "offset": [2202, 2210]}, {"key": "to-exercise", "type": "clause", "offset": [2279, 2290]}, {"key": "under-clause", "type": "clause", "offset": [2302, 2314]}, {"key": "section-1252", "type": "clause", "offset": [2327, 2341]}, {"key": "applicable-deadline", "type": "definition", "offset": [2404, 2423]}, {"key": "designation-of-a", "type": "clause", "offset": [2497, 2513]}, {"key": "development-candidate", "type": "definition", "offset": [2514, 2535]}, {"key": "affected-by", "type": "definition", "offset": [2626, 2637]}, {"key": "the-right", "type": "clause", "offset": [2750, 2759]}, {"key": "applicable-option", "type": "definition", "offset": [2849, 2866]}, {"key": "in-writing", "type": "clause", "offset": [2886, 2896]}, {"key": "the-collaboration", "type": "clause", "offset": [2929, 2946]}, {"key": "the-license", "type": "definition", "offset": [3004, 3015]}, {"key": "section-65", "type": "clause", "offset": [3041, 3052]}, {"key": "development-of-the", "type": "clause", "offset": [3078, 3096]}, {"key": "of-change", "type": "clause", "offset": [3142, 3151]}, {"key": "license-fee-payments", "type": "clause", "offset": [3221, 3241]}, {"key": "table-a", "type": "clause", "offset": [3259, 3266]}, {"key": "section-411", "type": "clause", "offset": [3584, 3597]}, {"key": "election-under", "type": "clause", "offset": [3676, 3690]}, {"key": "pursuant-to-section", "type": "definition", "offset": [3825, 3844]}, {"key": "respective-obligations", "type": "clause", "offset": [3989, 4011]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [4064, 4087]}, {"key": "provided-that", "type": "clause", "offset": [4089, 4102]}, {"key": "remedies-for-the", "type": "clause", "offset": [4219, 4235]}, {"key": "failure-of-a", "type": "clause", "offset": [4236, 4248]}, {"key": "in-accordance-with", "type": "definition", "offset": [4477, 4495]}, {"key": "the-development", "type": "clause", "offset": [4521, 4536]}, {"key": "exclusivity-covenants", "type": "clause", "offset": [4668, 4689]}, {"key": "exercise-of-an-option", "type": "clause", "offset": [4725, 4746]}, {"key": "technology-transfer-obligations", "type": "clause", "offset": [4809, 4840]}, {"key": "section-49", "type": "clause", "offset": [4853, 4864]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [4908, 4934]}, {"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [4990, 5028]}, {"key": "will-apply-to", "type": "clause", "offset": [5029, 5042]}, {"key": "license-granted", "type": "clause", "offset": [5052, 5067]}, {"key": "rights-hereunder", "type": "clause", "offset": [5105, 5121]}], "samples": [{"hash": "7yICmZPouEt", "uri": "/contracts/7yICmZPouEt#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "score": 29.1587953457, "published": true}], "snippet": "On a Collaboration Program-by-Collaboration Program basis, if, at any time during the Option Period, a Change of Control occurs involving Ionis and a Person that, at the time of the close of such Change of Control, is developing in human clinical trials or commercializing a Directly Competitive Collaboration Product within the Field or is engaged in a Directly Competitive Collaboration Program (such pre-existing Directly Competitive Collaboration Product, a \u201cPre-Existing Competitive Product\u201d) or, at any time during the Term after the closing of such Change of Control, develops or acquires a Directly Competitive Collaboration Product or begins a Directly Competitive Collaboration Program (such Person being hereinafter referred to as a \u201cCompeting Collaboration Acquirer\u201d) and such Competing Collaboration Acquirer has not, within [***] of either (i) the closing of the Change of Control in the event the Directly Competitive Collaboration Product is being developed in human clinical trials or commercialized, or the Directly Competitive Collaboration Program exists, as of such closing date or (ii) the date of first development or acquisition of such Directly Competitive Collaboration Product or the date on which such Competing Collaboration Acquirer begins such Directly Competitive Collaboration Program (the \u201cCollaboration Divestiture Period\u201d) divested itself of the Directly Competitive Collaboration Product or Directly Competitive Collaboration Program, or terminated development and commercialization of such Directly Competitive Collaboration Product or such Directly Competitive Collaboration Program, then (A) Ionis will provide written notice to Biogen of the closing of such Change of Control or Collaboration Divestiture Period, as applicable, (B) [***], (C) solely with respect to any Collaboration Program that relates to such Directly Competitive Collaboration Product or Directly Competitive Collaboration Program for which Initiation of IND-Enabling Toxicology Studies have not occurred, subject to Section 12.5.3, elect to have Ionis complete Ionis Activities under this Agreement for such Collaboration Program until such time as the applicable Collaboration Program is ready to begin IND-Enabling Toxicology Studies, after which Biogen may elect to exercise its rights under clause (D) of this Section 12.5.2 with respect to such Collaboration Program (in which case the applicable deadline for Biogen\u2019s notice under such clause will be extended until [***] after designation of a Development Candidate for such Collaboration Program), and (D) solely with respect to any Collaboration Product affected by such Directly Competitive Collaboration Product or Directly Competitive Collaboration Program, Biogen will have the right, within [***] following such written notice, to either:\n(a) if unexercised, exercise the applicable Option by notifying Ionis in writing of Biogen\u2019s election to license the Collaboration Product at a prorated license fee payment as compared to the license fee payment set forth in Section 6.5, based upon the stage of Development of the applicable Collaboration Product at the time of Change of Control or Collaboration Divestiture Period, as applicable, which license fee payments are set forth on Table A of Schedule 12.5 hereto. If Biogen exercises the applicable Option pursuant to this Section 12.5.2(a), Biogen will not be obligated [***]. Upon Biogen\u2019s exercise of its Option pursuant to this Section 12.5.2(a), Biogen will be deemed to have obtained and Ionis will be deemed to have granted the license set forth in Section 4.1.1; or\n(b) Allow such [***] period to lapse without providing any such notice of election under this Section 12.5.2, or otherwise provide Ionis with written notice within such period electing not to exercise the applicable Option pursuant to Section 12.5.2(a) above, in either of which cases, subject to Section 12.5.3, Ionis and Biogen will continue to exercise their rights and perform their respective obligations with respect to the Collaboration Product under the terms of this Agreement. Provided that Ionis complies with Section 12.5.3, Biogen\u2019s rights as set forth in this Section 12.5.2 shall be Biogen\u2019s exclusive remedies for the failure of a Competing Collaboration Acquirer to divest or terminate development and commercialization of a Directly Competitive Collaboration Product or Directly Competitive Collaboration Program during the Collaboration Divestiture Period in accordance with this Section 12.5.2, and the development or commercialization of a Pre-Existing Competitive Product by a Competing Collaboration Acquirer will not be a violation of Ionis\u2019 exclusivity covenants under Section 2.1.1. Upon Biogen\u2019s exercise of an Option pursuant to Section 12.5.2(a) above, Ionis will carry out its technology transfer obligations pursuant to Section 4.9 with respect to the Collaboration Product. For the avoidance of doubt, except as set forth in this Section 12.5.2, all other terms and conditions of this Agreement will apply to any such license granted pursuant to Biogen\u2019s exercise of its rights hereunder.", "hash": "d7e4238f79ab765d3c2e73ce81b5400f", "id": 9}, {"size": 1, "snippet_links": [{"key": "during-the-option-period", "type": "clause", "offset": [0, 24]}, {"key": "collaboration-program", "type": "definition", "offset": [31, 52]}, {"key": "responsible-for", "type": "clause", "offset": [98, 113]}, {"key": "activities-under", "type": "clause", "offset": [123, 139]}, {"key": "development-candidate-identification-plan", "type": "definition", "offset": [148, 189]}, {"key": "initial-development-plan", "type": "definition", "offset": [198, 222]}, {"key": "except-as-otherwise-provided", "type": "clause", "offset": [228, 256]}, {"key": "expenses-associated", "type": "definition", "offset": [293, 312]}], "samples": [{"hash": "hkdYULuTDOl", "uri": "/contracts/hkdYULuTDOl#collaboration-programs", "label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Isis Pharmaceuticals Inc)", "score": 24.8439425051, "published": true}], "snippet": "During the Option Period, on a Collaboration Program-by-Collaboration Program basis, Isis will be responsible for all Isis Activities under the ASO Development Candidate Identification Plan and the Initial Development Plan and, except as otherwise provided under Section 1.13.1, all costs and expenses associated therewith.", "hash": "a991fe6a3eaad44c0d16548b669d2c14", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih9jb2xsYWJvcmF0aW9uLXByb2dyYW1zIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"size": 31, "parents": [["collaboration-overview", "Collaboration Overview"], ["research-and-development", "Research and Development"], ["research-and-development-costs-paid-by-biogen", "Research and Development Costs Paid by Biogen"], ["research-and-development-under-the-alliance", "Research and Development Under the Alliance"], ["diligence", "Diligence"]], "children": [["", ""], ["general", "General"], ["costs", "Costs"], ["generally", "Generally"], ["animal-welfare", "Animal Welfare"]], "title": "Collaboration Programs", "id": "collaboration-programs", "related": [["development-program", "Development Program", "Development Program"], ["commercialization-plan", "Commercialization Plan", "Commercialization Plan"], ["collaboration", "Collaboration", "Collaboration"], ["research-program", "Research Program", "Research Program"], ["collaboration-activities", "Collaboration activities", "Collaboration activities"]], "related_snippets": [], "updated": "2025-07-07T12:37:48+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The Collaboration Programs clause defines the framework and expectations for joint initiatives or projects undertaken by the parties. It typically outlines how the parties will cooperate, share resources, and coordinate activities to achieve mutually agreed objectives, such as research, product development, or marketing efforts. By establishing clear guidelines for collaboration, this clause helps ensure effective teamwork, minimizes misunderstandings, and clarifies each party\u2019s roles and responsibilities within the program."}, "json": true, "cursor": ""}}